Summary: On June 12, 2026, MBX Biosciences reported one-year open-label extension data for once-weekly canvuparatide (MBX 2109), a parathyroid hormone (PTH) peptide prodrug in development for chronic hypoparathyroidism. The headline numbers are durable: responders to the 12-week Phase 2 Avail trial held their response through 52 weeks of open-label dosing, with calcium normalization, improvements in kidney markers, and bone-turnover changes consistent with physiologic PTH replacement. A Phase 3 registrational trial remains on track to begin in Q3 2026.
For a rare endocrine disease that has been managed for decades with high-dose oral calcium and active vitamin D, durable once-weekly PTH replacement is the story. The question Phase 3 will answer is whether the durability and tolerability hold up in a larger placebo-controlled trial designed to support a marketing application.
The news: one-year sustained response, Phase 3 on track
MBX announced in a June 12, 2026 press release that the open-label extension (OLE) of the Phase 2 Avail trial showed sustained calcium normalization at 12 months. The original 12-week Avail readout, reported in September 2025, showed 63% of canvuparatide-treated patients reaching the composite responder definition. By six months in the OLE, 79% met the responder criteria. The one-year data, presented at the 3rd Parathyroid Summit during ENDO 2026 in Chicago, shows that response holding, with additional improvements in kidney function and bone-turnover markers across the cohort.
Following a successful End-of-Phase 2 meeting with the FDA in March 2026, MBX confirmed Phase 3 trial design and timing. The registrational trial will randomize approximately 160 adults with chronic hypoparathyroidism in a 3:1 ratio to canvuparatide or placebo, with a four-week fixed-dose period (600 mcg weekly), an 18-week dose-titration period, and a four-week maintenance period before primary endpoint assessment at week 26. An open-label extension follows. The Phase 3 trial is on track to initiate in Q3 2026, with EMA Scientific Advice and orphan designations from both FDA and EMA already in hand (per the company's March 9, 2026 8-K).
What makes canvuparatide different from prior PTH replacement
Hypoparathyroidism patients have had two PTH options approved or in late-stage development before canvuparatide: full-length recombinant PTH(1-84) (formerly marketed as Natpara, withdrawn from U.S. sale due to manufacturing issues), and palopegteriparatide, an Ascendis Pharma long-acting prodrug of teriparatide (PTH 1-34) that received FDA approval in 2024 as Yorvipath.
Canvuparatide is a different molecule and a different release strategy. The active drug, as characterized in Molecular Metabolism 2026, is an extended PTH(1-32) peptide carrying a fatty acylated lysine at position 33. The prodrug undergoes a controlled-release intramolecular cyclization governed by temperature and pH, slowly releasing the active peptide after subcutaneous injection. Pharmacokinetic data from Phase 1 (PubMed 39574220) showed terminal half-life of 133 to 186 hours for the active peptide across dose groups, which is what makes once-weekly subcutaneous dosing pharmacologically plausible.
The point of all of this engineering is the exposure curve. Daily injections of teriparatide produce sharp peaks and deep troughs in PTH activity. Continuous infusion produces flat exposure but is not practical for chronic use. A weekly prodrug that releases active peptide gradually sits closer to the physiologic profile of a healthy parathyroid, which is the underlying goal of replacement therapy in hypoparathyroidism.
Why chronic hypoparathyroidism needs better options
Hypoparathyroidism is rare, with a U.S. prevalence estimated in the tens of thousands. The most common cause is surgical: thyroid or parathyroid surgery that damages or removes the parathyroid glands. Less common causes include autoimmune disease, genetic syndromes, and idiopathic forms.
The default therapy has not changed in decades. Patients take large doses of oral calcium, often several grams per day, plus active vitamin D analogs (calcitriol or alfacalcidol) to compensate for the absent PTH signal. This combination keeps serum calcium in range but does not restore physiologic regulation. Over years, patients accumulate complications: kidney stones, calcifications in soft tissues, impaired renal function, and abnormal bone remodeling. Quality of life is reduced. Acute hypocalcemic episodes can land patients in emergency rooms.
What's needed is a way to put PTH back into the system that does not require multiple injections per day. That is the brief canvuparatide is trying to fill. The June 12 OLE data are the first peptide-class durability signal that has held through 12 months in this disease setting outside of the now-approved Yorvipath.
Phase 3: what it will actually test
The Phase 3 design (registered at ClinicalTrials.gov NCT06465108 for Phase 2; Phase 3 protocol will be separately registered) is built around a composite primary endpoint that has become standard in this disease: the proportion of patients achieving normal serum calcium and independence from conventional therapy (i.e., off the high-dose oral calcium and active vitamin D). Secondary endpoints include normalization of urinary calcium, which is the marker that ties directly to long-term kidney protection.
The four-week fixed-dose period at 600 mcg is the key design choice. It says MBX has decided what an "average" weekly dose should look like before titration begins. The 18-week titration window then lets investigators adjust each patient's dose to maintain calcium homeostasis without supplements. The four-week maintenance period is the assessment window. If the 3:1 placebo control behaves as expected (i.e., placebo patients drop out of normocalcemia without active vitamin D), the trial is powered for a clear separation.
What can still go wrong: dosing too high causes hypercalcemia, the dose-titration period can be tricky to manage in a global multi-site trial, and the OLE phase is where any long-term safety signals — particularly bone or kidney effects — would emerge. The single-arm one-year OLE data announced June 12 are the strongest argument that those signals are not lurking, but they are not the same thing as a placebo-controlled 26-week registrational readout.
Commercial and clinical stakes
If canvuparatide reads out positively in Q3 2026 Phase 3 initiation and Phase 3 results follow on the same trajectory, it would enter a category where Ascendis Pharma's palopegteriparatide (Yorvipath) is already approved. Two long-acting PTH replacement therapies in the same indication would shift the commercial conversation from "is there a replacement option" to "which replacement option fits which patient." Dose-titration profile, injection device, patient calcium and kidney trajectories on long-term therapy, and price will all matter.
For prescribers, the clinical question is which patients benefit most from once-weekly PTH replacement versus continuing on conventional therapy. The OLE data hint at improvements in kidney function and bone markers — exactly the long-term complications that conventional therapy fails to prevent. If those signals hold up in Phase 3, the case for replacement therapy in patients with progressive kidney involvement gets stronger.
Related compounds and context
Readers tracking PTH replacement should also know about teriparatide (PTH 1-34, Forteo), the daily injected form approved for osteoporosis (a different indication using PTH's anabolic effect on bone rather than as a replacement therapy). Palopegteriparatide (Yorvipath, not currently in our directory) is the closest comparator and is already FDA-approved for chronic hypoparathyroidism. MBX's broader pipeline also includes imapextide (MBX 1416) for post-bariatric hypoglycemia and obesity programs MBX 4291 and MBX 5765 — all built on the same Precision Endocrine Peptide (PEP) prodrug platform that produces canvuparatide.
Frequently Asked Questions
What is canvuparatide?
Canvuparatide, also known as MBX 2109, is an investigational once-weekly parathyroid hormone (PTH) peptide prodrug developed by MBX Biosciences. It is designed to release a biologically active PTH analog gradually after subcutaneous injection, supporting long-term PTH replacement in chronic hypoparathyroidism.
Is canvuparatide FDA-approved?
No. As of June 2026, canvuparatide is investigational. It has FDA and EMA orphan drug designation for chronic hypoparathyroidism. A Phase 3 trial is expected to initiate in Q3 2026. Marketing approval, if it follows, would come after Phase 3 readout and a New Drug Application review.
How is canvuparatide different from teriparatide?
Teriparatide is daily-injected PTH(1-34) used for osteoporosis to drive anabolic bone formation, not for PTH replacement. Canvuparatide is once-weekly, releases a different active PTH analog from a prodrug, and is designed for sustained physiologic-style PTH replacement in hypoparathyroidism.
What was new in the June 12, 2026 data?
One-year results from the open-label extension of the Phase 2 Avail trial. Responders to the 12-week trial maintained calcium normalization at 52 weeks, with continued improvements in kidney function and bone turnover markers. The data were presented at the 3rd Parathyroid Summit during ENDO 2026 in Chicago.
When will Phase 3 read out?
MBX has stated Phase 3 will initiate in Q3 2026. The primary endpoint is assessed at week 26, so top-line results would not be expected before mid-to-late 2027 at the earliest, accounting for enrollment, randomization, and the dose-titration period.
Sources
- MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide (BioSpace, June 12, 2026)
- MBX 8-K Successful End-of-Phase 2 FDA Meeting (SEC, March 9, 2026)
- Discovery and characterization of canvuparatide, Mol Metab 2026
- MBX 2109 Phase 1 in healthy volunteers (PubMed)
- Avail Phase 2 trial (ClinicalTrials.gov NCT06465108)
Sources & References
- FDA PCAC Meeting Announcement (July 23-24, 2026)
- PBS: FDA to Weigh Easing Limits on Peptides Favored by RFK Jr.
- BioPharma Dive: FDA Peptides RFK Advisory Committee Restrictions
- RAPS: FDA Considers Adding a Dozen Peptides to Bulk Drug List
- Ars Technica: RFK Jr. Forces FDA to Reconsider 12 Peptides
- ProPublica: Peptide Safety Investigation
- New York Times: Peptide Ban FDA RFK Jr.
- SSRP Institute: FDA Announces Change in Status of 12 Peptides
- CNBC: RFK Jr. Peptides Hims Hers GLP-1
- USA Today: RFK Jr. FDA Peptides Explainer
